Pergolidum [Inn-Latin] en es it fr

Pergolidum [Inn-Latin] Brand names, Pergolidum [Inn-Latin] Analogs

Pergolidum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Pergolidum [Inn-Latin] Chemical_Formula


Pergolidum [Inn-Latin] RX_link

Pergolidum [Inn-Latin] fda sheet

Pergolidum_[Inn-Latin] FDA

Pergolidum [Inn-Latin] msds (material safety sheet)

Pergolidum_[Inn-Latin] MSDS

Pergolidum [Inn-Latin] Synthesis Reference

No information avaliable

Pergolidum [Inn-Latin] Molecular Weight

314.489 g/mol

Pergolidum [Inn-Latin] Melting Point

207.5 oC

Pergolidum [Inn-Latin] H2O Solubility

No information avaliable

Pergolidum [Inn-Latin] State


Pergolidum [Inn-Latin] LogP


Pergolidum [Inn-Latin] Dosage Forms


Pergolidum [Inn-Latin] Indication

Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.

Pergolidum [Inn-Latin] Pharmacology

Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.

Pergolidum [Inn-Latin] Absorption

Significant amount may be absorbed (evidence on bioavailability still lacking).

Pergolidum [Inn-Latin] side effects and Toxicity

Oral, rat LD50: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation.

Pergolidum [Inn-Latin] Patient Information

Pergolidum [Inn-Latin] Organisms Affected

Humans and other mammals